Abbott Laboratories Corporation

Abbvie Inc.

Other

Abbott Gmbh & Co Kg

Abbvie Bahamas Limited

Makoto, Aoyama

Richard W Dixon

Shankar Kumar

Chengbin Wu

Paul Robert Hinton

Jonathan P Belk

Maria A Argiriadi

Yan Chen

Tariq Ghayur

Jochen G Salfeld

David J Calderwood

Michael Roguska

Anna M Ericsson

Lee Daniel Arnold

Gavin C Hirst

Zehra Kaymakcalan

Kristine E Frank

Neil Wishart

George Avgerinos

Biqin C Li

David Wayne Borhani

Lu Wang

Stevan Wakefield Djuric

Kurt Ritter

Boris Labkovsky

Michael Michaelides

Alan Frank Gasiecki

Thomas D Gordon

Michael White

Adrian Hobson

Paul Rafferty

Michael M Friedman

James H Holms

John A Mankovich

Irini Akritopoulou-Zanze

Michael Morytko

Douglas H Steinman

Kelly Mullen

Hans Wolfgang Hoeffken

Dawn M George

Carol K Wada

Henry Q Zhang

Andrew Burchat

Michael R Michaelides

Hua Ying

Carolyn A Cuff

Terry L Melim

Emma Fung

Susan E Lacy

Xiaoyun Wu

Albert Collinson

Kevin Patrick Cusack

Robert V Talanian

Zhiren Xia

Peter Hrnciar

Alexander Robert Duncan

Makoto Takeshita

Vijaya J Gracias

Patrick Betschmann

Melanie A Muckey

Claude E Barberis

Karen Nazaretian Allen

Jürgen Dinges

Biqin Li

Kimba Lee Fischer

Lily K Abbott

Xiaolei Zhang

Tariq Ghayer

Simon Mark Brocklehurst

Celia Patricia Shorrock

Julia Elizabeth Thompson

Simon Nicholas Lennard

Eric C Brieinlinger

Andreas Loew

Adelaine Leung

Nancy J Bump

Cornelia Bellamacina

Kelly D Mullen

David W Borhani

Lu X Wang

Lee D Arnold

Aoyama Makoto

Kimba Fischer

The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.

Interleukin-13 binding proteins

The present invention is directed to novel aminopyrrolidines of formula I pharmaceutically acceptable salts thereof, metabolites thereof, isomers thereof, stereoisomers thereof or pro-drugs thereof, wherein the variables are as defined herein. The compounds of formula (I) are useful as chemokine receptor antagonists and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.

Aminopyrrolidines as chemokine receptor antagonists

The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.

IL-12/p40 binding proteins

Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1&#x3b1; and IL-1&#x3b2; and neutralize IL-1&#x3b1; and IL-1&#x3b2; activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting two different but structurally related antigens (e.g., IL-1&#x3b1; and IL-1&#x3b2;) and for inhibiting the activity of the antigens, e.g., in a human subject suffering from a disorder in which IL-1&#x3b1; and/or IL-1&#x3b2; activity is detrimental.

Dual specificity antibodies and methods of making and using

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.

Dual variable domain immunoglobulin and uses thereof

Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.

Indazole compounds

Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.

Antibodies that bind IL-18 and methods of inhibiting IL-18 activity

The present invention is directed to novel imidazopyrazine and imidazopyrimidine compounds of formula (I) wherein the variables are as defined herein. The compounds of formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.

Imidazo based heterocycles

Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1&#x3b1; and IL-1&#x3b2; and neutralize IL-1&#x3b1; and IL-1&#x3b2; activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting two different but structurally related antigens (e.g., IL-1&#x3b1; and IL-1&#x3b2; ) and for inhibiting the activity of the antigens, e.g., in a human subject suffering from a disorder in which IL-1&#x3b1; and/or IL-1&#x3b2; activity is detrimental.

Growing community of inventors

Jefferson, MA, United States of America

Richard W Dixon